“No treatment-related serious adverse events (SAEs) have been reported,” Contraline announced. “All observed adverse effects were consistent with the expected treatment profile,” which they compared to no-scalpel vasectomy. There were no unexpected safety concerns.
As reported by The Guardian, Jon Oatley, a professor at Washington State University’s School of Molecular Biosciences, pointed out that no public data confirms that the ADAM implant is reversible, and that researchers don’t know what the long-term effects of blocking the vasa deferentia are.
Oatley believes that most men would prefer a contraceptive pill. The good news? More options are becoming available. A new drug, YCT-529, from the University of Minnesota College of Pharmacy, is a hormone-free pill that stops the production of sperm, currently in mice trials.